- SIRT7, H3K18ac, and ELK4 Immunohistochemical Expression in Hepatocellular Carcinoma
-
Hye Seung Lee, Wonkyung Jung, Eunjung Lee, Hyeyoon Chang, Jin Hyuk Choi, Han Gyeom Kim, Aeree Kim, Baek-hui Kim
-
J Pathol Transl Med. 2016;50(5):337-344. Published online August 5, 2016
-
DOI: https://doi.org/10.4132/jptm.2016.05.20
-
-
8,367
View
-
153
Download
-
17
Citations
-
 Abstract
 PDF
- Background
SIRT7 is one of the histone deacetylases and is NAD-dependent. It forms a complex with ETS-like transcription factor 4 (ELK4), which deacetylates H3K18ac and works as a transcriptional suppressor. Overexpression of SIRT7 and deacetylation of H3K18ac have been shown to be associated with aggressive clinical behavior in some cancers, including hepatocellular carcinoma (HCC). The present study investigated the immunohistochemical expression of SIRT7, H3K18ac, and ELK4 in hepatocellular carcinoma.
Methods
A total of 278 HCC patients were enrolled in this study. Tissue microarray blocks were made from existing paraffin-embedded blocks. Immunohistochemical expressions of SIRT7, H3K18ac and ELK4 were scored and analyzed.
Results
High SIRT7 (p = .034), high H3K18ac (p = .001), and low ELK4 (p = .021) groups were associated with poor outcomes. Age < 65 years (p = .028), tumor size ≥ 5 cm (p = .001), presence of vascular emboli (p = .003), involvement of surgical margin (p = .001), and high American Joint Committee on Cancer stage (III&V) (p < .001) were correlated with worse prognoses. In multivariate analysis, H3K18ac (p = .001) and ELK4 (p = .015) were the significant independent prognostic factors.
Conclusions
High SIRT7 expression with poor overall survival implies that deacetylation of H3K18ac contributes to progression of HCC. High H3K18ac expression with poor prognosis is predicted due to a compensation mechanism. In addition, high ELK4 expression with good prognosis suggests another role of ELK4 as a tumor suppressor beyond SIRT7’s helper. In conclusion, we could assume that the H3K18ac deacetylation pathway is influenced by many other factors.
-
Citations
Citations to this article as recorded by  - Epigenomic interplay in tumor heterogeneity: Potential of epidrugs as adjunct therapy
Suvasmita Rath, Diptesh Chakraborty, Jyotsnarani Pradhan, Mohammad Imran Khan, Jagneshwar Dandapat
Cytokine.2022; 157: 155967. CrossRef - Distinct histone H3 modification profiles correlate with aggressive characteristics of salivary gland neoplasms
Aroonwan Lam-Ubol, Ekarat Phattarataratip
Scientific Reports.2022;[Epub] CrossRef - Acetyl-CoA: An interplay between metabolism and epigenetics in cancer
Yang Hao, Qin Yi, Xu XiaoWu, Chen WeiBo, Zu GuangChen, Chen XueMin
Frontiers in Molecular Medicine.2022;[Epub] CrossRef - Sirtuins (SIRTs) As a Novel Target in Gastric Cancer
Agata Poniewierska-Baran, Paulina Warias, Katarzyna Zgutka
International Journal of Molecular Sciences.2022; 23(23): 15119. CrossRef - Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma
Fang Wang, Peter Breslin S J, Wei Qiu
Liver Research.2021; 5(4): 195. CrossRef - Acute high folic acid treatment in SH-SY5Y cells with and without MTHFR function leads to gene expression changes in epigenetic modifying enzymes, changes in epigenetic marks, and changes in dendritic spine densities
Daniel F. Clark, Rachael Schmelz, Nicole Rogers, Nuri E. Smith, Kimberly R. Shorter, Lorenzo Chiariotti
PLOS ONE.2021; 16(1): e0245005. CrossRef - The E-Twenty-Six Family in Hepatocellular Carcinoma: Moving into the Spotlight
Tongyue Zhang, Danfei Liu, Yijun Wang, Mengyu Sun, Limin Xia
Frontiers in Oncology.2021;[Epub] CrossRef - Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
Yingying Wang, Qianying Zhu, Haihong Hu, Hong Zhu, Bo Yang, Qiaojun He, Lushan Yu, Su Zeng
Biochemical Pharmacology.2021; 188: 114546. CrossRef - HCG11 up-regulation induced by ELK4 suppressed proliferation in vestibular schwannoma by targeting miR-620/ELK4
Ruiqing Long, Zhuohui Liu, Jinghui Li, Yuan Zhang, Hualin Yu
Cancer Cell International.2021;[Epub] CrossRef - Downregulation of circular RNA circPVT1 restricts cell growth of hepatocellular carcinoma through downregulation of Sirtuin 7 via microRNA‐3666
Yong Li, Haitao Shi, Jia Yuan, Lu Qiao, Lei Dong, Yan Wang
Clinical and Experimental Pharmacology and Physiology.2020; 47(7): 1291. CrossRef - Clinicopathological and molecular analysis of SIRT7 in hepatocellular carcinoma
Masae Yanai, Morito Kurata, Yutaka Muto, Hiroto Iha, Toshinori Kanao, Anna Tatsuzawa, Sachiko Ishibashi, Masumi Ikeda, Masanobu Kitagawa, Kouhei Yamamoto
Pathology.2020; 52(5): 529. CrossRef - MicroRNA-148b Inhibits the Malignant Biological Behavior of Melanoma by Reducing Sirtuin 7 Expression Levels
Rui Sun, Meiliang Guo, Xiaojing Fan, Qinqin Meng, Dingfen Yuan, Xinrong Yang, Kexiang Yan, Hui Deng, Fengjie Sun
BioMed Research International.2020; 2020: 1. CrossRef - H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy
Marta Hałasa, Anna Wawruszak, Alicja Przybyszewska, Anna Jaruga, Małgorzata Guz, Joanna Kałafut, Andrzej Stepulak, Marek Cybulski
Cells.2019; 8(5): 485. CrossRef - Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells
Wenzhi Li, Zhe Sun, Chen Chen, Lin Wang, Zhimin Geng, Jie Tao
Biomedicine & Pharmacotherapy.2018; 100: 257. CrossRef - Identification of cancer-related potential biomarkers based on lncRNA-pseudogene-mRNA competitive networks
Cheng Wu, Yunzhen Wei, Yinling Zhu, Kun Li, Yanjiao Zhu, Yichuan Zhao, Zhiqiang Chang, Yan Xu
FEBS Letters.2018; 592(6): 973. CrossRef - SIRT7 suppresses the epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis by promoting SMAD4 deacetylation
Wenlu Li, Dandan Zhu, Shuaihua Qin
Journal of Experimental & Clinical Cancer Research.2018;[Epub] CrossRef - Sirtuin 7: a new marker of aggressiveness in prostate cancer
Romain Haider, Fabienne Massa, Lisa Kaminski, Stephan Clavel, Zied Djabari, Guillaume Robert, Kathiane Laurent, Jean-François Michiels, Matthieu Durand, Jean-Ehrland Ricci, Jean-François Tanti, Frédéric Bost, Damien Ambrosetti
Oncotarget.2017; 8(44): 77309. CrossRef
|
E-submission
